Physician profile
Connor Griffin
NPI 1376077818
$3,951.51
in general payments reported to CMS, 2019-2025
21 companies · $1,048 in 2025
The $1,048 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $485 · 2022: $797 · 2023: $633 · 2024: $988 · 2025: $1,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,668.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $775.17 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $584.84 | 2021-2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $527.93 | 2022-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $414.50 | 2021-2025 | Livtencity, Gattex |
| Janssen Biotech, INC. | $309.46 | 2021-2023 | Stelara |
| Ipsen Biopharmaceuticals, INC | $293.36 | 2024-2025 | Iqirvo, Bylvay |
| Gilead Sciences, INC. | $238.47 | 2024-2025 | |
| Madrigal Pharmaceuticals | $225.52 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $114.45 | 2021-2023 | Dificid, Prevymis |
| Boston Scientific Corporation | $95.98 | 2022 | |
| Eisai INC. | $87.92 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $54.85 | 2022-2023 | Rebyota |
| Janssen Scientific Affairs, LLC | $50.80 | 2022 | |
| Laborie Medical Technologies Corp. | $37.68 | 2024 | Renovarp |
| Veloxis Pharmaceuticals, INC. | $27.77 | 2025 | Envarsus |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $25.11 | 2022 | |
| Celgene Corporation | $23.31 | 2023 | |
| Exact Sciences Corporation | $18.03 | 2024 | |
| Eton Pharmaceuticals, INC. | $16.82 | 2025 | Betaine Anhydrous, Nitisinone, Carglumic Acid |
| Intra-Sana Laboratories | $16.26 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Medtronic, INC. | $13.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connor Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.